Arcutis (ARQT) Director Terrie Curran Sells $956k in Shares

Terrie Curran, a director at Arcutis Biotherapeutics (ARQT), sold shares valued at $956,000. The transaction is part of her strategy to liquidate a portion of her holdings. This sale reflects ongoing movements within the company’s leadership and could impact investor perception. Such significant sales may raise questions about insider confidence in the company's future performance. Investors often monitor insider trading activity as a gauge of sentiment regarding a company's prospects.